{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["1999"],"condition":["Cancer-Bowel-Back passage (rectum) or large bowel (colon)","Metastatic colorectal cancer treated with FOLFOXIRI"],"disease":["Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)","Metastatic Colorectal Cancer Treated With Folfoxiri"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2454318"],"location":["Italy"],"study_start_month":["5"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.","description":"Interventions: Observation: metastatic colorectal cancer patients who have been treated in first-line with FOLFOXIRI (a triple drug combination of irinotecan 165 mg/square meter (sqm) endovenous (ev) in 1 hour, oxaliplatin 85 mg/sqm ev in 2 hours and 5-fluorouracil 3200 mg/sqm as a 48-hour continous infusion ev plus leucovorin 200 mg/sqm ev in 2 hours, every 14 days for 12 cycles) and who underwent radical surgical resection of metastases will be followed up yearly for 5 years after the diagnosis of disease to collect their survival status.\nPrimary outcome(s): Overall survival[Anually for 5 years after diagnosis]\nStudy Design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective","dates":{"creation":"1999-05-15"},"accession":"2454318","cross_references":{"Australian New Zealand Clinical Trials Registry":["ACTRN12608000615381"]}}